Shots:
- The US FDA has approved Formosa’s clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat post-operative inflammation & pain following ocular surgery
- Sosei Heptares will receive a payment of $2.5M from Formosa on achieving the milestone as per the agreement signed b/w them
- APP13007 was initially developed by Activus Pharma (subsidiary of Sosei) using its Activus Pure Nanoparticle Technology. It was divested to Formosa in Aug 2017
Ref: PRNewswire | Image: Formosa Pharmaceuticals| Press Release
Related News:- The US FDA Approves Hugel’s Letybo for the Treatment of Glabellar Lines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
